16-Jan-2026
STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board Influence
Benzinga (Thu, 15-Jan 1:06 PM ET)
STAAR Surgical, Broadwood Partners enter cooperation pact
Seeking Alpha News (Thu, 15-Jan 9:43 AM ET)
Alcon Terminates Agreement to Acquire STAAR Surgical
Business Wire (Tue, 6-Jan 8:00 PM ET)
Business Wire (Tue, 6-Jan 9:52 AM ET)
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
Business Wire (Tue, 30-Dec 4:30 PM ET)
Business Wire (Fri, 19-Dec 12:59 PM ET)
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
Business Wire (Fri, 19-Dec 11:45 AM ET)
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
PRNewswire (Wed, 17-Dec 4:53 PM ET)
Business Wire (Wed, 17-Dec 1:17 PM ET)
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Alcon trades on the NYSE stock market under the symbol ALC.
As of January 16, 2026, ALC stock price declined to $79.00 with 1,365,148 million shares trading.
ALC has a beta of 0.86, meaning it tends to be less sensitive to market movements. ALC has a correlation of 0.29 to the broad based SPY ETF.
ALC has a market cap of $39.07 billion. This is considered a Large Cap stock.
Last quarter Alcon reported $3 billion in Revenue and $.79 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.03.
In the last 3 years, ALC traded as high as $101.10 and as low as $63.78.
The top ETF exchange traded funds that ALC belongs to (by Net Assets): EQTY, DFIV, DFAI, DFIC, DFAX.
ALC has underperformed the market in the last year with a return of -5.7%, while the SPY ETF gained +18.1%. In the last 3 month period, ALC fell short of the market, returning +4.8%, while SPY returned +5.0%. However, in the most recent 2 weeks ALC has outperformed the stock market by returning +1.8%, while SPY returned +1.2%.
ALC support price is $78.54 and resistance is $80.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALC shares will trade within this expected range on the day.
